– Mr. White will remain Executive Chairman of the Board – Mr. Ford has been elected to the Abbott Board ABBOTT PARK, Ill., Nov. 13, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second […]
Financial
Cardiovascular Systems, Inc. Announces Stephen Stenbeck Joins Board of Directors
Brent Blackey Retires after 12 Years of Service ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Stephen Stenbeck. He replaces independent director […]
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
– NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company’s Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today reported financial results for the third […]
UPDATE: InspireMD Announces Third Quarter 2019 Financial Results
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET TEL AVIV, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the […]
Neovasc Announces Third Quarter 2019 Financial Results
Recent Highlights · Delivered continued revenue growth for Neovasc ReducerTM (“Reducer”) · Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory angina · Reducer featured at the 40th Annual National Congress of the Italian Society of Interventional Cardiology · Announced Norman Radow joined the board of directors · Granted a […]
PLx Pharma Inc. Reports Third Quarter 2019 Results
Company on track for sNDA submission to the FDA by year-end SPARTA, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and […]
Shockwave Medical Reports Third Quarter 2019 Financial Results
SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2019. Recent Highlights Recognized revenue of $11.3 million […]
Endologix Reports Third Quarter 2019 Financial Results
Third Quarter Highlights Global revenue up 2.9% versus prior year Sequential AFX system sales increase in the U.S. Operating cash burn of $4.0M for the quarter IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the […]
Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer
Vancouver, Nov. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of Bill Little […]
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020 Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER, Colo., Nov. 06, 2019 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach […]



